

**REMARKS**

The Abstract has been rewritten in conventional U.S. format.

Claims 1-5 have been amended in order to write these claims in appropriate U.S. claim format and to eliminate multiple dependencies.


Claims 6-12 have been cancelled.

New Claims 13-30 have been added. Claims 13 and 14 correspond to original claim 6 written in singly dependent form. Claims 15 and 16 are drawn to the subject matter of original claims 7 and 12 written in conventional U.S. method-of-use format. Claims 17-20 are directed to the subject matter of original Claim 8 in method-of-use format. Claims 21-24, in method-of-use format, are drawn to the subject matter of original Claim 9. Claims 25-28 are directed to the subject matter of original claim 10 written in method-of-use format, and method-of-use claims 29-30 are drawn to the subject matter of original claim 11.

Claims 1-5 and 13-30 are in the application as amended.

Respectfully submitted,

Date: 10/4/04



Paul E. Dupont  
Reg. No. 27,438

Address  
Patent Department  
Sanofi-Synthelabo Inc.  
9 Great Valley Parkway  
Malvern, PA 19355  
Telephone No. (610) 889-6338  
Facsimile: (610) 889-8799